Mesothelin is limitedly expressed on mesothelial cells in different types of tissues including pleura, peritoneum, and pericardium but is highly expressed as a tumor-differentiation antigen in a broad spectrum of solid tumors, which make mesothelin as an attractive target for cancer immunotherapy (37). Here, MSLN is linked to neoplasm.